nach oben

Erschienen in:

16.04.2018 | Original Article

Polyfunctionality of CD4⁺ T lymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma

verfasst von: J. Doescher, S. Jeske, S. E. Weissinger, C. Brunner, S. Laban, E. Bölke, T. K. Hoffmann, T. L. Whiteside, P. J. Schuler, M.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

For head and neck squamous cell cancer (HNSCC), standard therapy consists of surgery, radiation, and/or chemotherapy. Antineoplastic immunotherapy could be an option in an adjuvant setting and is already in palliation. A functional immune system is a prerequisite for successful immunotherapy. However, effects of the standard-of-care therapy on the patients’ immune system are not fully understood.

Methods

Peripheral blood mononuclear cells (PBMC) were collected from patients with HNSCC (n = 37) and healthy controls (n = 10). PBMC were stimulated with staphylococcal enterotoxin B (SEB). Simultaneous expression of various cytokines was measured in CD4⁺ and CD8⁺ T cells by multicolor flow cytometry, and polyfunctional cytokine expression profiles were determined on a single-cell basis.

Results

Expression levels of all measured cytokines in CD4⁺ T cells were higher in patients after chemoradiotherapy (CRT) as compared to untreated HNSCC patients or normal controls. After CRT, the frequency of polyfunctional CD4⁺ T cells, which simultaneously expressed multiple cytokines, was significantly increased as compared to untreated patients (p < 0.01).

Conclusion

CRT increases polyfunctionality of CD4⁺ T cells in HNSCC patients, suggesting that standard-of-care therapy can promote immune activity in immune cells. These polyfunctional CD4⁺ T cells in the blood of treated HNSCC patients are expected to be responsive to subsequent immunotherapeutic approaches.

Nur mit Berechtigung zugänglich

Levy A, Blanchard P, Bellefqih S, Brahimi N, Guigay J, Janot F, Temam S, Bourhis J, Deutsch E, Daly-Schveitzer N, Tao Y (2014) Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. Strahlenther Onkol 190(9):823–831. https://doi.org/10.1007/s00066-014-0626-0 CrossRefPubMed

Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. https://doi.org/10.1200/jco.2016.68.1478

Popp I, Grosu AL, Niedermann G, Duda DG (2016) Immune modulation by hypofractionated stereotactic radiation therapy: therapeutic implications. Radiother Oncol 120(2):185–194. https://doi.org/10.1016/j.radonc.2016.07.013 CrossRefPubMed

Baumann R, Dunst J (2017) Radiotherapy enhances the effect of PD-1 checkpoint inhibitors. Strahlenther Onkol. https://doi.org/10.1007/s00066-017-1179-9 PubMedCentral

Zhang P, Su DM, Liang M, Fu J (2008) Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 45(5):1470–1476. https://doi.org/10.1016/j.molimm.2007.08.013 CrossRefPubMed

Ghadjar P, Pöttgen C, Joos D, Hayoz S, Baumann M, Bodis S, Budach W, Studer G, Stromberger C, Zimmermann F, Kaul D, Plasswilm L, Olze H, Bernier J, Wust P, Aebersold DM, Budach V (2016) Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers. Strahlenther Onkol 192(8):552–560. https://doi.org/10.1007/s00066-016-0999-3 CrossRefPubMed

De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, Moser S, Evans TG, Koup R, Miller CJ, Roederer M (2004) Vaccination in humans generates broad T cell cytokine responses. J Immunol 173((9):5372–5380CrossRefPubMed

Makedonas G, Betts MR (2006) Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol 28(3):209–219. https://doi.org/10.1007/s00281-006-0025-4 CrossRefPubMed

Laban S, Doescher J, Schuler PJ, Bullinger L, Brunner C, Veit JA, Hoffmann TK (2015) Immunotherapy of head and neck tumors: highlights of the ASCO Meeting 2015. HNO 63(9):612–619. https://doi.org/10.1007/s00106-015-0054-1 CrossRefPubMed

10.

Schuler PJ, Harasymczuk M, Schilling B, Lang S, Whiteside TL (2011) Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods 369(1–2):59–68. https://doi.org/10.1016/j.jim.2011.04.004 CrossRefPubMedPubMedCentral

11.

Schuler PJ, Schilling B, Harasymczuk M, Hoffmann TK, Johnson J, Lang S, Whiteside TL (2012) Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T‑cell subsets in cancer patients. Eur J Immunol 42(7):1876–1885. https://doi.org/10.1002/eji.201142347 CrossRefPubMedPubMedCentral

12.

Schuler PJ, Harasymczuk M, Schilling B, Saze Z, Strauss L, Lang S, Johnson JT, Whiteside TL (2013) Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res 19(23):6585–6596. https://doi.org/10.1158/1078-0432.ccr-13-0900 CrossRefPubMed

13.

Lissoni P, Brivio F, Fumagalli L, Messina G, Meregalli S, Porro G, Rovelli F, Vigore L, Tisi E, D’Amico G (2009) Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res 29(5):1847–1852PubMed

14.

Schmidt MA, Fortsch C, Schmidt M, Rau TT, Fietkau R, Distel LV (2012) Circulating regulatory T cells of cancer patients receiving radiochemotherapy may be useful to individualize cancer treatment. Radiother Oncol 104(1):131–138. https://doi.org/10.1016/j.radonc.2012.05.003 CrossRefPubMed

15.

Agarwal A, Rani M, Saha GK, Valarmathi TM, Bahadur S, Mohanti BK, Das SN (2003) Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest 32(1–2):17–30CrossRefPubMed

16.

Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96:41–101. https://doi.org/10.1016/s0065-2776(07)96002-2 CrossRefPubMed

17.

Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13(2):95–109. https://doi.org/10.1016/S1359-6101(01)00038-7 CrossRefPubMed

18.

Katayama A, Ogino T, Bandoh N, Nonaka S, Harabuchi Y (2005) Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer Res 11(8):2937–2946. https://doi.org/10.1158/1078-0432.ccr-04-1470 CrossRefPubMed

19.

Yannelli JR, Tucker JA, Hidalgo G, Perkins S, Kryscio R, Hirschowitz EA (2009) Characteristics of PBMC obtained from leukapheresis products and tumor biopsies of patients with non-small cell lung cancer. Oncol Rep 22(6):1459–1471CrossRefPubMed

20.

Hoffmann TK, Sonkoly E, Homey B, Scheckenbach K, Gwosdz C, Bas M, Chaker A, Schirlau K, Whiteside TL (2007) Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck 29(5):472–478. https://doi.org/10.1002/hed.20533 CrossRefPubMed

21.

Taniguchi K, Karin M (2014) IL‑6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 26(1):54–74. https://doi.org/10.1016/j.smim.2014.01.001 CrossRefPubMed

22.

Dong C (2008) TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8(5):337–348. https://doi.org/10.1038/nri2295 CrossRefPubMed

23.

Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, Wolf GT, Teknos TN (2008) Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113(4):750–757. https://doi.org/10.1002/cncr.23615 CrossRefPubMed

24.

Macchia I, Urbani F, Proietti E (2013) Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays. Biomed Res Int. https://doi.org/10.1155/2013/726239 PubMedPubMedCentral

25.

Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105(51):20410–20415. https://doi.org/10.1073/pnas.0810114105 CrossRefPubMedPubMedCentral

26.

Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107(12):4781–4789. https://doi.org/10.1182/blood-2005-12-4818 CrossRefPubMedPubMedCentral

Titel: Polyfunctionality of CD4+ T lymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma
verfasst von: J. Doescher
S. Jeske
S. E. Weissinger
C. Brunner
S. Laban
E. Bölke
T. K. Hoffmann
T. L. Whiteside
P. J. Schuler, M.D.
Publikationsdatum: 16.04.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 5/2018
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1289-z

Springer Medizin

Polyfunctionality of CD4⁺ T lymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma